328 related articles for article (PubMed ID: 8849454)
21. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
22. HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion.
vogt AB; Moldenhauer G; Hämmerling GJ; Kropshofer H
Immunol Lett; 1997 Jun; 57(1-3):209-11. PubMed ID: 9232453
[TBL] [Abstract][Full Text] [Related]
23. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
24. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
25. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
26. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.
Narayan K; Chou CL; Kim A; Hartman IZ; Dalai S; Khoruzhenko S; Sadegh-Nasseri S
Nat Immunol; 2007 Jan; 8(1):92-100. PubMed ID: 17143275
[TBL] [Abstract][Full Text] [Related]
27. Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules.
Sievers E; Neumann J; Raftery M; SchOnrich G; Eis-Hübinger AM; Koch N
Immunology; 2002 Sep; 107(1):129-35. PubMed ID: 12225371
[TBL] [Abstract][Full Text] [Related]
28. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
Neumann J; König A; Koch N
Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
[TBL] [Abstract][Full Text] [Related]
29. Identification of the HLA-DM/HLA-DR interface.
Davies MN; Lamikanra A; Sansom CE; Flower DR; Moss DS; Travers PJ
Mol Immunol; 2008 Feb; 45(4):1063-70. PubMed ID: 17870168
[TBL] [Abstract][Full Text] [Related]
30. DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.
Rinderknecht CH; Roh S; Pashine A; Belmares MP; Patil NS; Lu N; Truong P; Hou T; Macaubas C; Yoon T; Wang N; Busch R; Mellins ED
Immunology; 2010 Sep; 131(1):18-32. PubMed ID: 20408893
[TBL] [Abstract][Full Text] [Related]
31. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
32. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
Pashine A; Busch R; Belmares MP; Munning JN; Doebele RC; Buckingham M; Nolan GP; Mellins ED
Immunity; 2003 Aug; 19(2):183-92. PubMed ID: 12932352
[TBL] [Abstract][Full Text] [Related]
33. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
34. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
[TBL] [Abstract][Full Text] [Related]
35. Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases.
Lem L; Riethof DA; Scidmore-Carlson M; Griffiths GM; Hackstadt T; Brodsky FM
J Immunol; 1999 Jan; 162(1):523-32. PubMed ID: 9886429
[TBL] [Abstract][Full Text] [Related]
36. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
37. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
38. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.
Busch R; Rinderknecht CH; Roh S; Lee AW; Harding JJ; Burster T; Hornell TM; Mellins ED
Immunol Rev; 2005 Oct; 207():242-60. PubMed ID: 16181341
[TBL] [Abstract][Full Text] [Related]
39. HLA-DM and the MHC class II antigen presentation pathway.
Jensen PE; Weber DA; Thayer WP; Chen X; Dao CT
Immunol Res; 1999; 20(3):195-205. PubMed ID: 10741860
[TBL] [Abstract][Full Text] [Related]
40. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.
Muntasell A; Carrascal M; Alvarez I; Serradell L; van Veelen P; Verreck FA; Koning F; Abian J; Jaraquemada D
J Immunol; 2004 Jul; 173(2):1085-93. PubMed ID: 15240697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
